GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (TSE:4543) » Definitions » Altman Z-Score

Terumo (TSE:4543) Altman Z-Score : 6.76 (As of May. 03, 2024)


View and export this data going back to 1982. Start your Free Trial

What is Terumo Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 6.76 is strong.

Terumo has a Altman Z-Score of 6.76, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Terumo's Altman Z-Score or its related term are showing as below:

TSE:4543' s Altman Z-Score Range Over the Past 10 Years
Min: 2.9   Med: 5.02   Max: 7.08
Current: 6.76

During the past 13 years, Terumo's highest Altman Z-Score was 7.08. The lowest was 2.90. And the median was 5.02.


Terumo Altman Z-Score Historical Data

The historical data trend for Terumo's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo Altman Z-Score Chart

Terumo Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.50 5.29 5.45 5.52 5.07

Terumo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.43 5.07 6.04 5.32 6.10

Competitive Comparison of Terumo's Altman Z-Score

For the Medical Instruments & Supplies subindustry, Terumo's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terumo's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Terumo's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Terumo's Altman Z-Score falls into.



Terumo Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Terumo's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1878+1.4*0.5451+3.3*0.0784+0.6*8.3126+1.0*0.5233
=6.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was 円1,691,667 Mil.
Total Current Assets was 円669,012 Mil.
Total Current Liabilities was 円351,242 Mil.
Retained Earnings was 円922,094 Mil.
Pre-Tax Income was 39315 + 36623 + 29804 + 24037 = 円129,779 Mil.
Interest Expense was -799 + -1051 + -444 + -550 = 円-2,844 Mil.
Revenue was 239077 + 228621 + 215252 + 202216 = 円885,166 Mil.
Market Cap (Today) was 円3,953,935 Mil.
Total Liabilities was 円475,656 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(669012 - 351242)/1691667
=0.1878

X2=Retained Earnings/Total Assets
=922094/1691667
=0.5451

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(129779 - -2844)/1691667
=0.0784

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=3953934.750/475656
=8.3126

X5=Revenue/Total Assets
=885166/1691667
=0.5233

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Terumo has a Altman Z-Score of 6.76 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Terumo  (TSE:4543) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Terumo Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Terumo's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Terumo (TSE:4543) Business Description

Traded in Other Exchanges
Address
2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072
Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.

Terumo (TSE:4543) Headlines

No Headlines